News Focus
News Focus
Post# of 257257
Next 10
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

Re: DewDiligence post# 138189

Thursday, 05/03/2012 7:13:10 PM

Thursday, May 03, 2012 7:13:10 PM

Post# of 257257
Subcutaneous Actemra is non-inferior to IV formulation in ACR20 endpoint at 24 weeks:

http://finance.yahoo.com/news/genentech-reports-positive-study-actemra-050000943.html

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now